Novogen Limited (NVGN)
Melanoma is a form of cancer that begins in melanocytes (cells that make the pigment melanin). It may begin in a mole (skin melanoma), but can also begin in other pigmented tissues, such as in the eye or in the intestines.
The most dangerous aspect of melanoma is its ability, in later stages, to spread (or metastasize) to other parts of the body. The term 'metastatic melanoma', also known as Stage IV melanoma, is used when melanoma cells of any kind (cutaneous, mucosal or ocular) have spread through the lymph nodes to distant sites in the body and/or to the body's organs. The liver, lungs, bones and brain are most often affected by these metastases.
Immunotherapies (ipilumumab, vemurafenib, vaccines), chemotherapy (dacarbazine, vinblastine), radiotherapy and surgery are used to prolong life in Stage IV disease, but these modalities provide little benefit where metastases has occurred to the brain.
NVGN has confirmed that its lead candidate product, TRXE-009, originally developed for the treatment of brain cancers, has been shown in pre-clinical studies also to be highly active against melanoma.
NVGN's TRXE-009 has been confirmed as a potential new treatment for both adult and paediatric neural cancers. TRXE-009 previously has been announced as a world-first in having exceptionally high killing activity against adult brain cancer (glioblastoma multiforme) stem cells, and against the paediatric brain cancers - medulloblastoma and DIPG (diffuse interstitial pontine glioma) - all tumors that are highly resistant to known chemotherapies. According to NVGN, that same high potency is now confirmed against melanoma cells, with activity unaffected by the tumor's BRAF gene status.
TRXE-009 is a super-benzopyran compound generated by NVGN's VAL-ID (Versatile Approach to Library-based Iterative Design) drug discovery process, with structure-activity relationship driving design based on activity against brain cancer stem cells and the known required chemical criteria to facilitate passage across the blood-brain barrier.
NVGN will be delivering TRXE-009 as a proprietary construct known as Trilexium. Trilexium has been developed to maximise the bio-availability of the drug to cancer cells in the body. Animal xenograft studies of human cancer have confirmed the efficacy of Trilexium.
NVGN is a drug-development company. It has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs).
SBP compounds have been designed to kill the full heterogeneity of cells within a tumor, including the cancer stem cells. The molecular target is a trans-membrane electron-transfer pump mechanism oncogene that is common to all cancer cells. Cells die by respiratory distress and mitochondrial disintegration. The ATM compounds target the micro-filament component of the cancer cell's cytoskeleton and have been designed to combine with anti-microtubular drugs (taxanes, vinca alakaloids) to produce comprehensive and fatal destruction of the cancer cell cytoskeleton.
More about Novogen Limited (NVGN) at www.novogen.com
Procera Networks, Inc. (NYSEMKT:PKT)
PKT reported that it has received several-million dollars of orders from Tier 1 operators for 100GE-equipped PacketLogic(NYSE:TM) 20000 Platform.
These deployments will leverage the 100GE interfaces deployed in existing or new PL20000 systems delivering Subscriber Experience solutions for fixed and mobile operators. Most of the revenue from these orders is expected to be recognized in the fourth quarter of 2014.
The PacketLogic 20000 offers up to 600Gbps of capacity and up to 8 ports (4 channels) of 100GE interfaces, enabling a fixed or mobile operator to handle millions of subscribers traffic flows with full subscriber experience visibility in both real-time and with historical visibility into the subscriber experience metrics that matter.
PKT, the global Subscriber Experience company, is revolutionizing the way operators and vendors monitor, manage and monetize their network traffic.
Disclaimer: This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE-PR Finance www.finance.crwe-pr.com/disclaimer
Disclosure: The author has no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.